Mustafa Yavuz KÖKER, Berkay SARAYMEN, Sabahattin MUHTAROĞLU, Başak KOÇ ŞENOL, Bülent ZÜLFİKAR, Canan ALBAYRAK, Davut ALBAYRAK, Bülent ESER, Mustafa ÇETİN, Emine ZENGİN, Nazan SARPER, Semih YILMAZ, Aysun ÇETİN, Esma BENTLİ

Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of thirty-two Turkish patients with Glanzmann thrombasthenia: a multicenter experience

Background/aim: Glanzmann thrombasthenia (GT) is a rare autosomal recessively inherited bleeding disorder characterized by the quantitative (type 1 and type 2) or qualitative (type 3) deficiency in platelet membrane glycoprotein (GP) IIb/IIIa (CD41a/CD61) fibrinogen receptors. In type 1, 2, and 3, CD41a/CD61 expression is 5%, 5%–20% and above 20%, respectively. In this study, diagnosis of GT was confirmed and subgroups were identified in 32 Turkish patients by flow cytometry analysis. Materials and methods: CD41a/CD61 expression levels in platelet-rich plasma (PRP) obtained from peripheral venous EDTA blood samples were analyzed with a BD FACSCanto II flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). GT subgroup analysis was performed by counting 50,000 events in the BD FACSDiva Software v6.1.3 program of the instrument. Results: In the present study, in blood samples of 32 patients from 23 families with GT and 22 healthy controls, co-expression levels of CD41a and CD61 in PRP was analyzed. 12 out of 23 families were consistent with type 1 GT (52.2%), 4 were consistent with type 2 GT (17.4%), and 7 were consistent with type 3 GT (30.4%). Conclusion: Especially due to consanguineous marriages, GT with various glycoprotein levels may be detected. As a result of the flow cytometry analysis of the present study with the highest GT patient population in Turkey, type 1 GT patients were the most common subgroup. In the determination of the GT subgroups; especially in the detection of type 3 GT, flow cytometry is the most sensitive glycoprotein analysis method. In addition to light transmission aggregometry, CD41a/CD61 study by flow cytometer confirms diagnosis when mutation analysis cannot be performed.Key words: Glanzmann thrombasthenia, glycoprotein IIb/IIIa, flow cytometry, platelet-rich plasma

PDF

___

1. Glanzmann E. Hereditäre häemorrhagische thrombasthenie: ein beitrag zur pathologie der blutplättchen. Jahrbuch für Kinderheilkunde 1918; 88 (1): 113-141.(in German).
2. Nurden AT. Glanzmann thrombasthenia. Orphanet Journal of Rare Diseases 2006; 1 (10): 1-8. doi: 10.1186/1750-1172-1-10
3. Dash DP, Kumar A, Gupta B. Emergency craniotomy in Glanzmann thrombasthenia: anesthetic management and brief review of literature. Journal of Anaesthesiology Clinical Pharmacology 2016; 32 (4): 533-535. doi: 10.4103/0970- 9185.194763
4. King MW. Hemostasis blood coagulation. In: Weitz M, Edmonson KG (editors). Integrative Medical Biochemistry Examination and Board Review. 1st ed. New York, NY, USA: McGraw Hill Education; 2014. pp. 820-825.
5. Caen JP, Castaldi PA, Lecrec JC, Inceman S, Larrieu MJ et al. Congenital bleeding disorders with long bleeding time and normal platelet count: I. Glanzmann’s thrombasthenia (report of fifteen patients). The American Journal of Medicine 1966; 41 (1): 4-26. doi.org/10.1016/0002-9343(66)90003-9
6. Patel D, Väänänen H, Jirouskova M, Hoffmann T, Bodian C et al. Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood 2003; 101 (3): 929-936. doi: 10.1182/blood.V101.3.929
7. George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood 1990; 75 (7): 1383-1395. doi: 10.1182/blood.V75.7.1383.bloodjournal7571383
8. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. British Journal of Haematology 1974; 28 (2): 253-260. doi: 10.1111/j.1365- 2141.1974.tb06660.x
9. Philips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71 (4): 831-843.
10. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118 (23): 5996-6005. doi: 10.1182/ blood-2011-07-365635
11. Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Review of Hematology 2012; 5 (5): 487-503. doi: 10.1586/ehm.12.46
12. Nurden AT, Ruan J, Pasquet KM, Gauthier B, Combrié R et al. A novel 196Leu to Pro substitution in the beta3 subunit of the alphaIIbbeta3 integrin in a patient with a variant form of Glanzmann thrombasthenia. Platelets 2002; 13 (2): 101-111. doi: 10.1080/09537100220122466
13. Diz-Küçükkaya R. Inherited platelet disorders including Glanzmann thrombasthenia and Bernard-Soulier syndrome. Hematology American Society of Hematology Education Program 2013; 2013 (1): 268-275. doi: 10.1182/ asheducation-2013.1.268
14. Haghighi A, Borhany M, Ghazi A, Edwards N, Tabaksert A et al. Glanzmann thrombasthenia in Pakistan: molecular analysis and identification of novel mutations. Clinical Genetics 2016; 89 (2): 187-192. doi: 10.1111/cge.12622
15. Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann’s thrombasthenia in Israel. Blood 1991; 77 (1): 75-83. doi: 10.1182/blood.V77.1.75.75
16. Stevens RF, Meyer S. Fanconi and Glanzmann: the men and their works. British Journal of Haematology 2002; 119 (4): 901- 904. doi: 10.1046/j.1365-2141.2002.03812.x
17. Nurden AT, Nurden P. Inherited disorders of platelets an update. Current Opinion in Hematology 2006; 13 (3): 157-162. doi: 10.1097/01.moh.0000219661.80785.e3
18. Kannan M, Saxena R. Glanzmann’s thrombasthenia: an overview. Clinical and Applied Thrombosis/Hemostasis 2009; 15 (2): 152-165. doi: 10.1177/1076029608326165
19. Di Minno G, Coppola A, Di Minno MN, Poon MC. Glanzmann’s thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thrombosis and Haemostasis 2009; 102 (6): 1157-1164. doi: 10.1160/TH09-04-0225
20. Grainger JD, Trachil J, Will AM. How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. British Journal of Haematology 2018; 182 (5): 621-632. doi: 10.1111/bjh.15409
21. Poon MC, Di Minno G, D’Oiron R, Zotz R. New insights into the treatment of Glanzmann thrombasthenia. Transfusion Medicine Reviews 2016; 30 (2): 92-99. doi: 10.1016/j. tmrv.2016.01.001
22. Kutlubay B, Özdemir NG, Tüysüz G, Apak H, Celkan T. Glanzmann thrombasthenia: Cerrahpaşa Medical Faculty experience. Turkish Archives of Pediatrics 2012; 47 (2): 106- 108. doi: 10.4274/tpa.823
23. Tokgöz H, Torun OD, Çalışkan U, Akar N. Novel mutations of integrin αIIb and β3 genes in Turkish children with Glanzmann’s thrombasthenia. Platelets 2015; 26 (8): 779-782. doi: 10.3109/09537104.2014.998994
24. Kannan M, Ahmad F, Yadav BK, Anand M, Jain P et al. Glanzmann’s thrombasthenia in North Indians: sub classification and carrier detection by flow cytometry. Platelets 2009; 20 (1): 12-15. doi: 10.1080/09537100802434853
25. Hassan HO, Al-Mudalal SS, Alubaidy YG, Al-Rahal NK. Expression of CD41 (GPIIb) and CD61 (GPIIIa) in patients with Glanzmann thrombasthenia using flow cytometry. Iraqi Journal of Medical Sciences 2016; 14 (3): 266-275.
26. Arias EG, Butta N, Gonzalez C, Larrucea S, Ayuso MS et al. Competition between normal (674C) and mutant (674R) GPIIb subunits: role of the molecular chaperone BiP in the processing of GPIIb-IIIa complexes. Blood 2001; 97 (9): 2640- 2647. doi: 10.1182/blood.v97.9.2640
27. Farsinejad A, Farajollahi MM, Kazemi A, Saemi N, Faranoush M. Different biochemical expression pattern of platelet surface glycoproteins suggests molecular diversity of Glanzmann’s thrombasthenia in Iran. Blood Coagulation & Fibrinolysis 2013; 24 (6): 613-618. doi: 10.1097/MBC.0b013e328360a558
28. Vijapurkar M, Ghosh K, Shetty S, McLane MA, Moura da Silva AM et al. A simple, novel and robust test to diagnose type I Glanzmann thrombasthenia. Haematologica 2008; 93 (5): 797- 798. doi: 10.3324/haematol.12288
29. Lobo V, Shetty S, Kulkarni B, Ghosh K. A novel ELISA for diagnosis of Glanzmann’s thrombasthenia and the heterozygote carriers. Annals of Hematology 2012; 91 (6): 917- 921. doi: 10.1007/s00277-011-1390-1